Therapeutic efficacy of modified anti-miR21 in metastatic prostate cancer.
This study aimed to investigate the stability and therapeutic efficacy of the modified LNA- and PNA-type anti-miRs in a murine prostate cancer model under various treatment conditions. After verifying the anti-cancer potential of anti-miR21 by targeting tumor suppressor PTEN, the potential of the modified LNA- and PNA-type anti-miR21s was compared in vitro and in vivo. We found that PNA-type anti-miR21 showed better stability and therapeutic efficacy in the xenografted mouse tumor model than the LNA-type anti-miR21. Furthermore, PNA-type anti-miR21 treatment showed reduced tumor metastasis. This study may serve as a ground for exploring diverse choices in therapeutic oligonucleotide modification techniques to improve cancer treatment. PMID: 32736696 [PubMed - as supplied by publisher]
We examined the association between androgen deprivation therapy (ADT) use and the risk of mild cognitive impairment (MCI) among prostate cancer patients. METHODS: We included 241 cognitively unimpaired men, aged 70 to 90, with a history of prostate cancer before enrollment in the population-based Mayo Clinic Study of Aging. Using the Rochester Epidemiology Project medical records-linkage system, ADT use and length of exposure were abstracted. Follow-up visits occurred every 15 months and MCI diagnoses were made based on clinical consensus. Cox proportional hazards models, with age as the timescale, were used to examin...
Publication date: November 2020Source: Biomedicine &Pharmacotherapy, Volume 131Author(s): Alina Jaglanian, Deborah Termini, Evangelia Tsiani
Condition: Prostate Cancer Intervention: Drug: 11C-Choline Sponsor: Beijing Cancer Hospital Not yet recruiting
ConclusionsThe alkalinity of tumor microenvironment plays an important role in anticancer efficiency of AA in CRPC. 18F-DFA PET/CT imaging could predict the therapeutic response of PCa animal model through illustration of tumoral uptake of AA. 18F-DFA might be a potential PET tracer in clinical diagnosis and treatment for CRPC.
British Journal of Cancer, Published online: 23 September 2020; doi:10.1038/s41416-020-01081-3Examination of potential novel biochemical factors in relation to prostate cancer incidence and mortality in UK Biobank
British Journal of Cancer, Published online: 23 September 2020; doi:10.1038/s41416-020-01086-yBCAS2, a protein enriched in advanced prostate cancer, interacts with NBS1 to enhance DNA double-strand break repair
ConclusionsSignificant risks of metastasis and prostate cancer mortality exist in untreated men beyond 10 years after diagnosis, but are not equally distributed among racial/ethnic groups.
ConclusionspcPET tracers present potential utility in the differential diagnosis, estimation of prognosis, evaluation of recurrence and treatment planning in patients with glioma. These radiotracers may hold a complementary role in conjunction with advanced MRI techniques in the non-invasive grading of gliomas.
First, and perhaps most importantly, Dinh et al are to be applauded for presenting their prospective series of men treated with proton therapy at the University of Washington and their carefully reported rectal toxicity outcomes in the context of dose-volume histogram analysis as well as differing rectal immobilization devices.1 These result s provide strong evidence suggesting that without the use of a rectal spacer, there is increased rectal toxicity with proton therapy compared with intensity modulated radiation therapy (IMRT).